News

TB R&D Weekly Update: Results from First Novel Regimen Trial Published

Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Click here to read the full press release.

Tackling TB: Developing the First Novel Drug Regimen from TB Alliance on Vimeo.

Additional TB R&D News:

Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects (IAC Abstract)

TB drugs chalk up rare win

Eradicate TB Through Public Awareness Campaigns: Educate The Public

Africa: Global Fund Results Show Broad Gains

More News
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Center for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...
29 Jul 2020
The WGND is announcing a call for applications to become a part of the WGND Core Group (CG). The CG provides leadership and sets the strategic direction for the work of the WGND. Addmitted applicants will begin their term in September 2020. Current CG membership information is available on the WGND...